Fisun Anna Gennadievna

Bashlakova E.E., Davidovskaya M.V., Evdoshenko E.P., Polyakova K.I., Skoromets A.A., Solodun I.Y., Fisun A.G., Khachanova N.V., Holownia M.A. 1475

Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme ‘7 high-cost nosologies’ on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care.

Davidovskaya M.V., Ermolaeva T.N., Kokushkin K.A., Fisun A.G., Holovnja-Voloskova M.J. 168

Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare, Moscow, Russia

Bashlakova E.E., Davidovskaya M.V., Evdoshenko E.P., Polyakova K.I., Skoromets A.A., Solodun I.Y., Fisun A.G., Khachanova N.V., Holownia M.A. 1475

Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme ‘7 high-cost nosologies’ on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care.

Davidovskaya M.V., Ermolaeva T.N., Kokushkin K.A., Fisun A.G., Holovnja-Voloskova M.J. 168

Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare, Moscow, Russia